Michele Holcomb Buys 93,944 Shares of PureTech Health (LON:PRTC) Stock
PureTech Health plc (LON:PRTC - Get Free Report) insider Michele Holcomb purchased 93,944 shares of the stock in a transaction dated Wednesday, July 29th. The stock was acquired at an average price of GBX 1 per share, for a total transaction of £939. 44.
August 1, 2026 by InsiderTrades. comPureTech Health plc (LON:PRTC-Get Free Report) insider Michele Holcomb bought 93,944 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were bought at an average cost of GBX 1 per share, with a total value of £939. 44. Michele Holcomb also recently made the following trade(s):On Wednesday, July 8th, Michele Holcomb purchased 31,481 shares of PureTech Health stock. The shares were bought at an average price of GBX 119 per share, for a total transaction of £37,462. 39. PureTech Health Stock Down 0. 4%PRTC stockopened at GBX 119. 12 on Friday. PureTech Health plc has a fifty-two week low of GBX 104. 71 and a fifty-two week high of GBX 146. 40. The company's 50 day moving average price is GBX 127. 34 and its 200 day moving average price is GBX 126. 66. The company has a debt-to-equity ratio of 6. 33, a quick ratio of 2. 51 and a current ratio of 6. 59. The firm has a market capitalization of £289. 96 million, a price-to-earnings ratio of -2. 59 and a beta of 0. 79. Analyst Upgrades and DowngradesSeparately, Peel Hunt restated a "buy" rating and issued a GBX 508 target price on shares of PureTech Health in a report on Monday, July 13th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of GBX 508. View Our Latest Report on PRTCAbout PureTech Health(Get Free Report)PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia. Featured StoriesFive stocks we like better than PureTech HealthChevron’s Strong Quarter Shows Why It Still Leads the Energy SectorAmazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull CaseApple’s Record Quarter Could Not Outrun Its Guidance ProblemMcKesson's Compounding Keeps Adding UpThis instant news alert was generated by narrative science technology and financial data from InsiderTrades. com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to[email protected]. Insider Buying or Selling at PureTech Health?Sign-up to receive InsiderTrades. com's daily insider buying and selling report for PureTech Health and related companies. From Our Partners